Highlights from the Biennial International Congress on Schizophrenia Research (ICOSR), March 24-March 28, 2017

Clin Schizophr Relat Psychoses. 2017 Summer;11(2):91-94. doi: 10.3371/CSRP.HH.071717.

Abstract

The 2017 International Congress on Schizophrenia Research, held in San Diego, California (March 24-28, 2017), attracted over 900 attendees from 34 countries. With the gracious assistance of Congress president James Meador-Woodruff, we bring you the following reports on the prospects for new drugs to treat schizophrenia.

Publication types

  • Congress

MeSH terms

  • Antipsychotic Agents / therapeutic use*
  • Benzophenones / therapeutic use
  • Biomedical Research
  • Catechol O-Methyltransferase Inhibitors / therapeutic use*
  • Clinical Trials as Topic
  • Clozapine / therapeutic use
  • Cognitive Dysfunction / drug therapy*
  • Cognitive Dysfunction / psychology
  • Drug Discovery
  • Fatty Acids, Omega-3 / therapeutic use*
  • Humans
  • Nitrophenols / therapeutic use
  • Piperazines / therapeutic use
  • Pregnenolone / therapeutic use
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Sodium Channel Blockers / therapeutic use*
  • Tolcapone

Substances

  • Antipsychotic Agents
  • Benzophenones
  • Catechol O-Methyltransferase Inhibitors
  • Fatty Acids, Omega-3
  • Nitrophenols
  • Piperazines
  • Sodium Channel Blockers
  • Pregnenolone
  • Tolcapone
  • cariprazine
  • Clozapine